TABLE 1.
The characteristics of the patients received sorafenib with or without TACE
| Sorafenib | Sorafenib with TACE | P | |
|---|---|---|---|
| Number of patients | 17 | 27 | |
| Gender (M/F) | 15/2 | 23/4 | 1.000 |
| Age (IQ)(range) | 60 (53‐65.5) (35‐760) | 59 (51‐62) (38‐78) | .649 |
| Child classification | 1.000 | ||
| A | 16 | 26 | |
| B | 1 | 1 | |
| hepatitis | .359 | ||
| B | 13 | 19 | |
| C | 3 | 2 | |
| B + C | 1 | 3 | |
| N | 0 | 3 | |
| Radiotherapy (yes/no) | 6/11 | 16/11 | .216 |
| Tumor status | |||
| Number | 2.7 ± 2.0 | 3.4 ± 2.2 | .489 |
| Diameter (cm) | 6.5(3.4‐12.5) (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) | 6.2(3.5‐13.5)(1.8‐14.2) | 1.000 |
| Lung metastasis | 9 (52.9%) | 12 (44.4%) | .811 |
| PVT | 5 (29.4%) | 11 (40.7%) | .611 |
| LN metastasis | 1 (11.8%) | 2 (7.4%) | .634 |
| HVT + IVCT | 3 (17.6%) | 2 (7.4%) | .359 |
| Carcinomatasis | 1 (5.9%) | 2 (7.4%) | 1.000 |
| Neutrophil (%) [median(IQ)(range)] | |||
| Before treatment | 63.9(52‐69.6)(44.3‐80.7) | 65.8(57.6‐73.4)(42.6‐84.9) | .596 |
| Post‐treatment a | 67.7(54.2‐72.2)(41.4‐90.7) | 64.7(57.8‐73.5)(45.2‐93.0) | .789 |
| Lymphocytes (%) | |||
| Before treatment | 24.3(21.5‐36.3)(11.5‐47.3) | 20.3(15.9‐34.2)(7.3‐46.8) | .394 |
| Post‐treatment a | 19.5(16.0‐32.6)(4.6‐45.2) | 23.0(13.4‐33.2)(4.3‐42.2) | .803 |
| N/L | |||
| Before treatment | 2.72(1.43‐3.19)(0.94‐7.02) | 3.29(1.66‐4.53)(0.92‐11.63) | .394 |
| Post‐treatment a | 3.50(1.58‐3.86)(0.92‐19.72) | 3.00(1.51‐5.63)(0.21‐21.6) | .978 |
Abbreviations: HVT, hepatic vein thrombus; IQ, interquartile; IVCT, inferior vena cava thrombus; LN, lymph node; N, negative for hepatitis B and C; N/L, neutrophil‐to‐lymphocyte ration; PVT, portal vein thrombus; TACE, transcatheter arterial chemoembolization.
a
One month after treatment.